Related Experiment Video

Updated: Aug 18, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Mutated PI 3-kinases: cancer targets on a silver platter

Sohye Kang1, Andreas G Bader, Li Zhao

  • 1Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA.

Cell Cycle (Georgetown, Tex.)
|May 7, 2005
PubMed

Insights

Targeting mutated PI3K p110alpha in cancer is promising. Specific inhibitors can target oncogenic forms, potentially leading to effective anti-cancer drugs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The phosphoinositide 3-kinase (PI3K) signaling pathway is frequently dysregulated in various cancers.
  • Hot spot mutations in the p110alpha catalytic subunit of PI3K are observed in approximately 30% of solid tumors.
  • These mutations often lead to enhanced enzymatic activity, activating downstream Akt signaling and promoting cancer development.

Purpose of the Study:

  • To investigate the role of PI3K p110alpha mutations in cancer.
  • To explore the potential of targeting mutated p110alpha with specific inhibitors.

Main Methods:

  • Analysis of PI3K p110alpha mutations in cancer datasets.
  • Biochemical assays to characterize the enzymatic activity of wild-type and mutated p110alpha.
  • In silico screening for small molecule inhibitors targeting mutated p110alpha.

Main Results:

  • Confirmed that prominent p110alpha mutations result in a gain of enzymatic function.
  • Demonstrated that these mutations activate oncogenic signaling pathways, including Akt.
  • Identified mutated p110alpha proteins as suitable targets for selective small molecule inhibitors.

Conclusions:

  • Mutated PI3K p110alpha is a key driver in a significant subset of solid tumors.
  • Development of specific inhibitors that differentiate between oncogenic and wild-type p110alpha is a viable therapeutic strategy.
  • Targeted inhibition of mutated p110alpha holds potential for developing novel and effective anti-cancer therapies.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...